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Objective: S100A4 is a Ca-binding protein that regulates cell growth, survival, and motility. The abundant
expression of S100A4 in rheumatiod arthritis contributes to the invasive growth of joint tissue and to bone
damage. In the present study, we analysed the role of S100A4 in bone homeostasis. Methods: Peripheral
quantitative computed tomography and histomorphometric analysis were performed in mice lacking the
entire S100A4protein (S100A4KO) and inwild-type (WT) counterparts treatedwith shRNA-lentiviral constructs
targeting S100A4 (S100A4-shRNA). Control groups consisted of sex-matched WT counterparts and WT mice
treated with a non-targeting RNA construct. Results: S100A4 deﬁciency was associated with higher trabecular
and cortical bonemass, increased number and thickness of trabeculi combined with larger periosteal circumfer-
ence and higher predicted bone strength. S100A4 inhibition by shRNA led to an increase in cortical bone in WT
mice. S100A4-deﬁcieny was associated with a reduced number of functional osteoclasts. S100A4KO and
S100A4-shRNA-treated bone marrow progenitors gave rise to a large number of small TRAP+ cells with few
nuclei and few pseudopodial processes. Poor osteoclastogenesis and the low resorptive capacity in S100A4Ko
mice may be linked to low levels of surface integrins, impaired adhesion capacity, and poor multinucleation
in S100A4-deﬁcient osteoclasts, as well as a low content of proteolytic enzymes cathepsin K and MMP3 and
MMP9 to break down the organic matrix. Conclusion: S100A4 emerges as a negative regulator of bone metabo-
lism potentially responsible for the excessive bone turnover in conditions marked by high levels of S100A4
protein, such as inﬂammation and rheumatoid arthritis.© 2013 Elsevier B.V. All rights reserved.1. Introduction
S100A4, a 101-amino-acid protein, is a member of the S100 family
of calcium-binding proteins [1,2]. S100A4 has initially attracted atten-
tion as a metastasis promoting protein, being later reported in con-
nection with pulmonary disease, kidney and liver ﬁbrosis, arthritis
and neuronal injuries. Under physiological conditions, S100A4 is re-
quired for cell motility, cell differentiation, and tissue remodelling. It
is expressed in the cells with a mobile phenotype, such as endothelial
cells, ﬁbroblasts and leukocytes [1]. Additionally, high expression
levels of S100A4 are observed during cell differentiation, in mesen-
chymal bone marrow cells, and in angiogenesis and organogenesis.gy and Inﬂammation Research,
teborg, Sweden. Tel.: +46 31
. Bokarewa).
rights reserved.Similarly to other members of the S100 family, the functions of
S100A4 are mediated through the interaction of the protein with its
binding partners. S100A4 directly interacts with cytoskeletal proteins,
such as actin, tropomyosin, and non-muscle myosin, and participates
in cytoskeletal rearrangements, cell shape changes, and motility. For
example, S100A4 binds tropomyosin and non-muscle myosin II in a
Ca2+-dependent manner to inhibit the actin-regulated ATPase activ-
ity of myosin II [3,4]. The binding of S100A4 to non-muscle myosin
promotes the disassembly of myosin ﬁlaments [3,5] and, in the presence
of chemoattractants, enhances cell polarisation aswell as directedmigra-
tion. S100A4 is located at the leading edge of migrating cells, where it
induces the formation of ﬂexible protrusions [6]. S100A4 interacts
with transcription factors p53, p37, methionine aminopeptidase 2, and
serpins (e.g., matrix metalloproteinases and urokinase) [2]. Binding of
S100A4 to these transcription factors can lead to activation as well as in-
hibition of their function. In addition, extracellular S100A4 is a potent in-
ducer of chemokines, metalloproteinases and urokinases [7–9]. These
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ceptor of advanced glycation end products (RAGE) and activating the
NF-kB signalling pathway. Interaction between S100A4 and transitory
annexin II exposed on the extracellular membrane surface is proposed
as a potential RAGE-independent mechanism of cell activation [10].
Rheumatoid arthritis (RA) is characterised by synovial hyperplasia
caused by proliferating synovial lining cells and by an accumulation of
inﬂammatory cells such as macrophages and T and B lymphocytes.
Synovial hyperplasia contributes to the progressive destruction of
joint cartilage and underlying subarticular bone in RA. Increased ex-
pression of S100A4 has been recently found in rheumatoid synovial
ﬁbroblasts and synovial tissues from RA patients [11,12]. Compared
to the expression of other S100 proteins such as S100A7, S100A8/
S100A9 and S100A12, S100A4 expression is predominant in rheuma-
toid synovial tissues. Importantly, plasma and synovial ﬂuid of RA
patients contain S100A4 in a bioactive oligomeric conformation [13].
The molecular role of S100A4 in the pathogenesis of RA is thought to
be linked to the regulation of cell motility, adhesion, apoptosis, and pro-
liferation, the properties that promote cancer and metastasis [14]. Con-
sistent with this hypothesis, high levels of S100A4 in RA patients are
associated with expression of other tumour-related proteins, survivin
and Flt3-ligand, which have an established role in the pathogenesis of
RA [15]. It is hypothesised that circulating S100A4 modulates target
cells towards a more aggressive phenotype, particularly by promoting
the production of proteolytic enzymes and matrix metalloproteinases,
which are required for matrix degradation and joint destruction
characteristic of severe RA. Indeed, S100A4 levels directly correlate
to persistent disease and to progressive bone destruction inside in-
ﬂamed joints [15]. A regression analysis indicated high levels of
S100A4 as a sensitive predictive parameter of radiographic joint
damage in RA. Additionally, S100A4-deﬁcient mice are protected from
subarticular bone destruction and from the systemic loss of bonemineral
content during septic arthritis [16]. The present study further assesses
the role of S100A4 in the regulation of bone mass in vivo.
Bone formation is a result of the collaborative activities of two
major cell types: osteoblasts and osteoclasts [17–19]. Bone undergoes
continuous remodelling. Osteoblasts produce proteins of the extracellu-
lar collagenous matrix, such as bone sialoprotein and type I collagen,
which are later mineralised under the control of osteocalcin and osteo-
pontin by the deposition of hydroxyapatite crystals. Osteoblast forma-
tion is controlled by a combination of cytokines and hormones, of
which insulin-like growth factors and Wnt proteins/low-density lipo-
protein receptor-related protein 5 (LRP5) seem to be of major impor-
tance. Osteoclasts break down mineralised extracellular collagenous
matrix, resorbing old bone and permitting its replacement with new
bone. The differentiation of mononuclear osteoclast precursors into
multinuclear mature osteoclasts is regulated by M-CSF, which stimu-
lates osteoclast precursor proliferation and induces the expression of
RANK and the ligand of the receptor activator of nuclear factor-kB
(RANKL) [17]. RANKL availability is regulated by osteoprotegerin
(OPG), which functions as a soluble decoy receptor. Osteoclast matura-
tion leads to its tight attachment to the surface of bone and to the
formation of a sealing zonemarked by an F-actin ring and a rufﬂed bor-
der, which are essential for the extracellular resorption of the mineral
matrix [17,18]. The attachment and rufﬂed border formation requires
expression of matrix osteopontin (OPN), and integrins, located in the
podosomes of osteoclasts. The most prominent integrins expressed by
mature osteoclasts are the α1β2 (CD49/CD18) and αvβ3 (CD51/CD61)
heterodimers. Acidiﬁcation of the osteoclast sealing zone and the
concomitant release of proteolytic enzymes, especially the cysteine pro-
tease, cathepsin K, and matrix metalloproteinases (MMPs), are crucial
for breaking down the organic matrix [19].
The underlying mechanisms for the role of S100A4 in bone
remodelling have recently been proposed [20,21]. The transcription
of S100A4 is regulated by the canonical Wnt/β-catenin pathway
[22,23], which is the major mechanism controlling the formation ofosteoblasts. S100A4 is also an essential mediator of Wnt-LPR5/
6-β-catenin signalling effects [22]. Mesenchymal cells committed to os-
teoblast differentiation express high levels of S100A4 mRNA, which is
undetectable in mature osteoblasts and osteocytes after the formation
of a mineralised matrix. Expression of S100A4 is associated with the in-
hibition of mineralisation, while intracellular inhibition of S100A4 in a
mouse osteoblastic cell line increases activation of the transcription fac-
tors Runx2 and Osterix [21] and the expression of bone sialoprotein and
osteocalcin which are essential proteins of mature osteoblasts [7,20].
Several observations argue for the role of S100A4 in osteoclast formation
and bone resorption. Firstly, intracellular interaction between S100A4
and liprin-β1 [4] potentiates the expression of integrins αv and α5
[24,25], the most prominent integrins expressed by mature osteoclasts.
Integrins promote osteoclast survival and cytoskeletal remodelling dur-
ing matrix adhesion [2]. Secondly, extracellular S100A4 up-regulates
the production of OPN [7], a matrix protein required for the attachment
and rufﬂed border formation of osteoclasts. In addition, cross talk be-
tween the S100A4/RAGE complex and bone matrix protein 2 signalling
regulates the expression of intracellular chloride channels 4 [26], which
are essential for the acidiﬁcation of the resorptive cavity of osteoclasts.
Finally, S100A4 regulates the synthesis of MMPs crucial for breaking
down the organic matrix at the transcriptional [27,28] and at the para-
crine levels [29].
This study focuses on the role of S100A4 in the regulation of bone
mass in vivo, and on the functional changes of bone remodelling cells
related to the absence of S100A4. Using S100A4KO mice and mice in
which S100A4 transcription was suppressed by shRNA, we found that
a deﬁciency of S100A4was associatedwith increased bonemass forma-
tion in trabecular and cortical bone compartments, accompanied by
a decrease in the expression of integrins essential for resorptive pit
sealing, and of bone resorptive enzymes, such as cathepsins and matrix
metalloproteinases.
2. Material and methods
2.1. Mice
S100A4KO mice were generated by a germ-line inactivation of the
S100A4 gene (Mts-1) as previously described [30] The clones containing
deletion of the S100A4 genewere aggregated with the eight-cell embry-
os followed by implantation into pseudopregnantmice. Germ-cell trans-
missionwas proved by tail biopsy and S100A4KOmiceweremaintained
by intercrossing of littermates. Breeding pairs of S100A4KO andWTmice
of congenic A/sn strain were kindly provided by Dr. Mariam Grigorian,
Institute of Cancer Biology, Copenhagen, Denmark. The mice were bred
and housed in the animal facility of the Department of Rheumatology
and Inﬂammation Research, University of Göteborg, under standard
conditions of temperature and light, and were fed laboratory chow
and water ad libitum. To assure that the phenotypic differences were
not caused by drifting of the strains following long-term parallel breed-
ing S100A4KO and WT mice were intercrossed to generate congenic
homozygous, heterozygous and wild-type siblings. All animal studies
were approved by the Animal Experimental Board of the University of
Göteborg.
2.2. In vivo inhibition of S100A4 transcription
Two lentiviral constructs containing two different sequences
encoding shRNA targeting S100A4 gene transcripts were prepared
by Sigma-Aldrich (St. Louis, MO. MissionTRC, TRCN0000011859 and
TRCN0000011860, respectively). shRNA sequences are available on
the website www.sigmaaldrich.com. WT mice (8 weeks old, 7 females
and 8 males) were treated with a combination of the two types of
lentiviral particles, 2 × 106 transduction particles in 100 μl/mouse
injected intra-peritoneally, once weekly for 5 consecutive weeks. The
control groups received the same titre of non-targeting lentiviral
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in bone marrow cells was tested by qPCR and by Western blot.
2.3. Treatment of mice with MMP inhibitor
WTmice (5 males and 5 females, 5 weeks-old) were orally treated
with a broad-spectrum MMP inhibitor PD166793 (Tocris Biosciences,
Bristol, UK) in the dose 30 mg/kg/day for 28 day, as previously de-
scribed [31]. This inhibitor binds to the catalytic site of the enzyme
and has high inhibitory activity to MMP2, MMP3 and MMP13, and
weak inhibitory activity to MMP1 and MMP9.
2.4. Reagents
For ﬂow cytometry analysis following anti-mouse antibodies have
beenused: RANK (R12-31, Biolegend, SanDiego, CA, USA), CD61 (2C9.G2,
Becton-Dickinson, Franklin Lakes, NJ, USA), CD62L (MEL-14, BD), CD3
(145-2C11, BD), CD49e (5H10-27, BD), CD49b (HMα2, BD), CD29
(HMb1-1, BD), B220 (RA3-6B2, BD), CD18 (C71/16, BD), as well as rat
IgG2β,κ, which served as an isotype control for RANK staining. Monoclo-
nal antibodies conjugated with PE, APC, PB, APC-H7, FITC, eFluor450,
PerCp, PeCy7, or biotin, were used. For ﬂow cytometry purposes also
streptavidin conjugated with APC (Becton-Dickinson) was utilised. For
in vitro osteoclastogenesis, recombinant murine sRANKL and recombi-
nant murine M-CSF were purchased from PeproTech. All culture plates
as well as chamber slides were purchased from Nunc.
2.5. Serological parameters
Serum levels of markers of bone turnover and immunological
markers were assessed in serum samples from experiment termination.
Osteocalcin, a bone formation marker, was analysed with a mouse
IRMA kit (Immutopics Inc., San Clemente, CA), CTX-I, a collagen type I
degradation fragment, was assessed with a Ratlaps ELISA kit (IDS
Nordic, Herlev, Denmark). Osteopontin (OPN, DY441), osteoprotegerin
(OPG, DY459), RANK-ligand (RANKL, DY462),matrixmetalloproteinase
3 (MMP3, MMP300), MMP9 (DY909), IGF-1 (DY791) and soluble
L-selectin (CD62L, DY576) were analysed with ELISA duo-sets (RnD
Systems, Minneapolis, MN).
2.6. Bone marrow isolation and cell analysis
Cells obtained via ﬂushing of the bone marrow cavity of both femo-
ral and tibial boneswith PBS, and lysis of erythrocyteswith 0.83%NH4Cl
in Tris buffer, were used for osteoclastogenesis or ﬂow cytometry.
2.7. In vitro osteoclastogenesis
Bone marrow cells were ﬁrst seeded on cell culture plastic for 3 h
to adhere stromal cells. Later non-adherent cells were harvested,
counted and cultured in the complete α-MEM supplemented with
M-CSF (10 ng/ml) for 48–72 h. Osteoclast differentiationwas initiated
by the addition of sRANKL (0–100 ng/ml) for different time periods.
Bone marrow cells of WT and S100A4KO mice were cultured in the
presence of recombinant S100A4 (0–0.01–0.1 ng/ml). Cells were sub-
mitted to phenotype analysis by ﬂow cytometry, and tomorphological
evaluation. For TRAP staining an acid phosphatase kit (Sigma-Aldrich,
St Luis, MO, USA) was used. Mature osteoclasts were identiﬁed as
TRAP-positive multinuclear cells and their number was calculated
(Leica DMR microscope with LeicaQWin software, Leica, Heidelberg,
Germany). For immunoﬂuorescence, osteoclast cultures were treated
as described (24) and subjected to a double staining procedure. In
brief, anti-S100A4 antibodies (ab27957, Abcam, Cambridge, UK), or
anti-β3-integrin antibodies (ab47584, Abcam) was followed by sec-
ondary goat-anti-rabbit IgG-AlexaFluor555 antibody (A21428, Life,
Paisley, UK). Actin ﬁlaments were stained with phallacidin-Bodipy FL(Life). Slidesweremountedwith Prolong gold antifade reagent contain-
ing 4′,6-diamidino-2-phenylindole for nuclear staining (Life). Normal
rabbit IgG (Dako, Glostrup, Denmark)was used as negative isotype con-
trols. Images were collected using a confocal microscope (LSM700;
Zeiss, Oberkochen, Germany). The background ﬂuorescence level was
set with the negative controls and images were analysed using the soft-
ware provided by Zeiss.
2.8. Flow cytometry
Bonemarrow cells or cultured cellswere resuspended in FACS buffer
(containing 1% FCS, 0,1% NaN3, 0,5 mM EDTA), and incubated with rat
anti-mouse CD16/32 (Fc-block, BD Pharmingen) for elimination of
non-speciﬁc binding of antibodies to Fc-receptors. The cells were then
incubated with indicated antibodies. Stained cells were analysed using
FACSCanto machine and FACSDiva software (BD). All analyses were
performed using the FlowJo software (Tree Star Inc., Ashland, OR,
USA) and gatingwas based on appropriate ﬂuorescenceminus one con-
trols. Bone marrow leukocytes were retrieved as described before [32].
2.9. Gene expression analysis
Total RNA from bone marrow cells was extracted using an RNeasy
Mini Kit (Qiagen, Valencia, CA) according to the manufacturer's instruc-
tions. The concentration and quality of the RNA were evaluated with
Nanodrop Spectrophotometer (Thermo Scientiﬁc, USA) and Experion
(Bio-Rad laboratories Inc., USA). 400 ng RNAwas used for cDNA synthe-
sis using a High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). Real-time ampliﬁcation was performed with RT2 SYBR®
Green qPCR Mastermix (Qiagen) using a ViiA™7 Real-Time PCR System
(Life). The RT-PCR reaction was performed using 200 nM of forward
and reverse primers, and 4 ng total RNA in a ﬁnal volume of 25 μl. The
expression of the following genes was measured: Csf1, Ctsk, Ctsl,
Mmp2, Mmp3, Mmp9, Mmp13, Plau, RANKL, Runx2, LRP5, Itga5, Itgb1,
Itgb2, Itgb3, Plaur, S100A4. Expression levels of these genes were
normalised to the reference genes, Gapdh and Ppia. The sequences of
primers used in real-time PCR are available from SABiosciences (Qiagen)
upon request, except for: Mmp2: 5′-CATCGCCCATCATCAAGTT-3′ and
5′-GGGCAGCCATAGAAAGTGTT-3′, Mmp13: 5′-TGATGAAACCTGGACAA
GCA-3′ and 5′-CCTGGGTCCTTGGAGTGAT-3′, LRP5: 5′-GCTGCTGCTGGT
GCTGTACT-3′ and 5′-CATCCACTAGCCGCACATC-3′. A negative control
(no template) reaction was performed for each primer pair tested. A
melting curve for each PCR was performed between 60 °C and 95 °C to
ensure that only a single product had been ampliﬁed. The results were
expressed as the fold change compared with the expression levels in
the WT control cells with the ddCq-method.
2.10. Peripher quantitative computed tomography (pQCT)
Left femur was subjected to computed tomographic scan using
Stratec pQCT XCT Research M software (Norland, Fort Atkinson, WI)
at a resolution of 70 μm, as described [33]. Trabecular and cortical volu-
metric BMC and BMD, bone geometry, and strength strain (moment of
inertia and moment of resistance) were assessed. Trabecular bone
was determined with a metaphyseal scan, at a point located 3% of
the length of the femur from the growth plate, and a density thresh-
old of 280 mg/cm3. Cortical BMDwas deﬁned with a mid-diaphyseal
scan taken 7 mm from the distal end of the femur at density thresh-
old of 710 mg/cm3. This mid-diaphyseal scan permitted assessment
of cortical BMD, BMC, cortical thickness, cortical area, endocortical
and periosteal perimeters, and bone strength.
2.11. Microcomputed tomography (micro-CT)
The left femoral bone was scanned and reconstructed into a
three-dimensional structure with Skyscan1176 micro-CT (Bruker,
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50 kV/499 mA, with a 0.2 mm aluminium ﬁlter. Exposure time was
795 ms. The X-ray projections were obtained at 0.3° intervals with
a scanning angular rotation of 180°. The projection images were
reconstructed into three-dimensional images using NRECON soft-
ware (version 1.5.1; Bruker). The reconstructed dataset was seg-
mented by an automated thresholding algorithm and analysed
with CT-Analyzer (version 1.7; Bruker). The analysis was performed
on a region of interest (ROI) chosen as a 1.4 mm slice starting 2%
from the proximal growth plate. The trabecular compartment ROI
was obtained by shrinking the total bone volume by 30 voxels
from the outside. The parameters measured and calculated were as
follows: (1) tissue volume and (2) trabecular volume was calculated
by the marching cubes method. The pictures were obtained with the
software CT-Vox (Bruker) using the total bone volume ROI.2.12. Histomorphometric analysis
Left femurs were collected, transferred in 70% ethanol and embed-
ded in methylmethacrylate. Longitudinal sections of the undecalciﬁed
bone were cut using rotation microtome (Leica) with tungsten carbide
blade. The undecalciﬁed sections were stained by a modiﬁed Masson–
Goldner trichrome technique and subjected to static histomorphometry
by Pharmatest Service (Turku, Finland). Bone histomorphometric
measurements were performed in the distal femur metaphysis using
OsteoMeasure histomorphometric system (Osteometrics, Atlanta, ver-
sion 2.2, USA). Three consecutive ﬁelds with the total area of 0.75 mm2
weremeasured along the vertical axis of the central metaphysis. Trabec-
ular width and trabecular number were calculated [34]. Sections were
used for evaluation of osteoblast and osteoclast number and activity.2.13. Morphology and immunohistochemistry
At the end of experiments, femoral bones were collected and
ﬁxed in 4% (w/w) formaldehyde, decalciﬁed with 10% (w/v) EDTA
in 0.1 M Tris-buffer (pH 6.95), routinely processed and embedded
in parafﬁn. For immunohistochemistry staining, 4 μm tissue sections
were deparafﬁnised and for osteocalcin staining epitope retrieval by
trypsin treatment was performed. Endogenous peroxidase was depleted
by incubating with 3% H2O2 followed by an overnight incubation with a
titrated amount of primary antibodies to cathepsin K (ab19027, Abcam)
or osteocalcin (LS-C17044, LifeSpanBiotechnology, Seattle,WA,USA). Fol-
lowing washing, the sections were incubated with ImmPRESS anti-rabbit
IgG (Vector Laboratories Inc., Burlingame, CA). Colour reaction was
completed with impact AEC (Vector). Sections were counterstained
with hematoxylin. TRAP staining was performed using Naphtol AS-BI
phosphate (Fluka N-2250) on deparafﬁnised tissue sections. Cathepsin
K-positive and TRAP-positive cells were enumerated within three
consecutive ﬁelds in the metaphyseal, diaphyseal, and in the growth
plate areas, using a Leica DMRmicroscope and the LeicaQWin software.
Enumeration of nuclei in TRAP positive cells was done along the growth
plate of the 4 μ (2 dimensional) femoral sections. Cells with ≥3 nuclei
were considered multinuclear.Fig. 1. S100A4-deﬁciency results in increased bone mass. (A) Peripheral quantitative compu
pared to wild-type (WT) mice. The measurements of total BMD, trabecular BMD and corti
10 + 10 males of each genotype. BMD of WT mice treated with lentiviral transduction p
n = 15) and showed an increase of cortical bone after 5 weeks of treatment compared to W
*P b 0.05, **P b 0.01, ***P b 0.001, S100A4KO vs. WT, Mann–Whitney test, median [IQR]. (B
mice and levelled-off with ageing. *P b 0.05, **P b 0.01 unpaired t-test, values are mean ± SE
is shown in bonemarrow ofWTmice treatedwith non-targeting RNA construct (NT, 1, 2, 3), W
load of 20, 10, and 5 μg/lane. (D) The ratio of density S100A4/actin indicates a 50% reduction in
7 weeks old) was subjected to Masson–Goldner trichrome staining and histomorphometry. A
mice is shown. Arrows indicate trabeculi (Tr). (F) Trabecular number and trabecular thickness
puter tomography of the left femoral bone of S100A4KO andWTmice (females, 9 weeks old) s
ular volume was increased in S100A4KO mice. *P b 0.05, **P b 0.01, S100A4KO vs. WT, Mann–2.14. In vitro migration assay
The migratory capacity of bone marrow cells was tested using the
TranswellTM system with a pore size of 3 μm (Corning Inc., Corning,
NY, USA) as previously described [35]. In short, bone marrow cells
(5 × 105/well) were placed in the upper chamber and migrated for
1, 3, and 15 h towards M-CSF (50 ng/ml) or 0.1% BSA–PBS dilution
buffer as negative control added in the lower chamber. To exclude
chemokinesis, M-CSF (50 ng/ml) was included in a set of wells in
both lower and upper chambers. Migrated cells were collected from the
lower chamber and subjected to phenotype analyses by ﬂow cytometry
as described above.
2.15. Statistical analysis
Values are reported as mean ± SD or median [IQR]. Comparisons
between groups were performed using the paired t-test or Mann–
Whitney U test. The proportion of multinuclear TRAP positive cells
was examined with Chi2 test. A p value of b0.05 was considered
signiﬁcant.
3. Results
3.1. S100A4-deﬁcient mice have increased bone mass
Peripheral quantitative computer tomography (pQCT) of the femur
showed a signiﬁcantly higher total bone mineral density (BMD) in
S100A4KO mice than in age and sex-matched congenic WT mice
(Fig. 1A, Supplementary Table 1). This elevated BMD was consistently
measured in male (mg/mm3: 474 ± 11 for S100A4 vs 428 ± 4 for WT,
p b 0.001) and in female (mg/mm3: 530 ± 11 for S100A4 vs 493 ± 7
forWT, p b 0.05) S100A4KOmice. To exclude parallel breeding as a rea-
son for the observed differences in BMD, S100A4KO and WT mice were
crossed. The BMD in 10-week-old F2 offspring was consistently higher
in animals with the S100A4KO genotype than in their WT siblings
(mean percent difference, 3–17%) (Supplementary Fig. S1A). The BMD
measurements in mice of different ages showed that the bone mass
difference between S100A4KO and WT mice was signiﬁcant at an early
age (weeks 10–20), but decreased by week 25 (Fig. 1B, Supplementary
Table 1).
To prove the absence of S100A4 to be the key event responsible for
the increase in bone mass in S100A4KO mice, WT mice (n = 15, age
8 weeks) were treated intraperitoneally with lentiviral shRNA trans-
duction constructs, which enabled silencing of S100A4 gene transcrip-
tion and a 54% reduction in S100A4 protein levels in shRNA-treated
mice (Fig. 1C, 1D). BMD assessed by pQCT 5 weeks later, showed a
16% increase in cortical bone mass (p = 0.0007. Fig. 1A) compared to
controlWTmice treated with non-targeting constructs, while no differ-
ence was seen in trabecular bone mass.
A higher BMD was measured in the trabecular and cortical bone
compartments of S100A4KOmice compared to WT (Fig. 1A). Trabec-
ular density in S100A4KOmales was higher and reached 128% of that
in the WT counterparts, while cortical parameters were enhanced in
females (Supplementary Fig. S1B). The cortical compartment in the
mid-diaphyseal region of S100A4KO mice was larger compared toted tomography indicated higher bone mineral density (BMD) in S100A4KO mice com-
cal area of femur BMD are presented for 12–16 week-old mice, 10 + 10 females and
articles producing shRNA against S100A4 (2 × 106 particles/week, intra-peritoneally,
T siblings treated with the same amount of non-targeting lentiviral particles (n = 7).
) The difference in total BMD between S100A4KO and WT mice was present in young
M, n = 4–10 mice/group, pooled genders. (C) Western blot analysis of S100A4 and actin
Tmice treatedwith S100A4-targeting shRNA (mice 1, 2, 3) and S100A4KOmouse. Protein
S100A4-shRNA treated mice. (E) Left femoral bone of S100A4KO andWTmice (females,
representative picture of trabecular bone in the metaphyseal region of S100A4KO andWT
was higher in S100A4KOmice, while space between trabeculi was smaller. (G)Microcom-
howed an increase in bone content in S100A4KOmice. Consistently, the tissue and trabec-
Whitney test, median [IQR], n = 7–10 mice/group.
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quently increased cortical area (mm3: 0.86 ± 0.02 vs 0.78 ± 0.01,
p b 0.01; Fig. 1A). Bone strength predicted from geometric measures
obtained with pQCT was greater in S100A4KO mice than in WT mice
with respect to bending (moment of inertia, p = 0.013) and twisting
(moment of resistance, p = 0.025) (Fig. 2F). Histomorphometric analy-
sis of the undecalciﬁed trabecular bone in the femoral metaphysealregion revealed a higher number of trabecules in S100A4KO mice
(Fig. 1E, F). Those trabecules were thicker and reduced signiﬁcantly the
inter-trabecular space. These ﬁndings were supported by a micro-CT
analysis of the distal femoral metaphysis. Three-dimensional trabecular
architecture in S100A4KO and WT mice showed higher tissue volume
and higher trabecular volume in S100A4KO mice (Fig. 1G), which are
consistent with the osteopetrotic phenotype of S100A4KO mice.
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osteolytic capacity in S100A4-deﬁcient mice
Histomorphometric analysis of the undecalciﬁed trabecular bone
following Masson–Goldner staining showed a high number of
trabecular-adherent osteoblasts in S100A4KO mice than in WT mice
(p = 0.003) (Fig. 2A), while the number of osteoclasts was similar in
WT and S100A4KO mice. Immunostaining of the decalciﬁed femoral
bone revealed comparable numbers of osteocalcin + osteoblasts in
S100A4KO and WT mice (Fig. 2B), while a signiﬁcantly lower number
of TRAP+ cells was found in the growth plate and in the trabecular
bone of S100A4KO mice (Fig. 2C). Additionally, TRAP+ cells of
S100A4KO mice were infrequently multinuclear; analysis of femoral
bone sections showed that only 6% of the S100A4KO TRAP+ cells had
≥3 nuclei, compared to 42% of theWT TRAP+ cells (p b 0.001)(Fig 2B3).
Staining for cathepsin K, the main cysteine protease of the osteoclast re-
sorptive pit, revealed signiﬁcant low number of cathepsin K+ cells in
S100A4KO mice compared to WT mice (Fig. 2D). The difference in the
number of cathepsinK+cellswas pronounced in the growthplate region
and along cortical bone. These morphological ﬁndings were consistent
with lower mRNA levels for the bone-resorptive proteins cathepsin K
(Fig. 2E1), and metalloproteinase MMP13 measured in the bone marrow
of S100A4KO mice (Fig. 2E2).
3.3. Low levels of MMPs do not account for the increased bone mass in
S100A4 deﬁcient mice
The expression of MMPs showed a signiﬁcant variation in the
bone marrow of S100A4KO mice; MMP13 mRNA was low, while
MMP3 and MMP9 were high (Fig. 2E2). The serum levels of MMP3
and MMP9 were strikingly low in S100A4KO mice (Fig. 2F, Supple-
mentary Table 2). Induction of MMPs is attributed to the extracellular
functions of S100A4 [36]. The ability of S100A4KO cells to respond to
stimulation with recombinant S100A4 was tested in bone marrow
cultures. Stimulation with recombinant S100A4 induced similar and
dose-dependent induction of MMP2 and MMP9 mRNA in WT and
S100A4KO bone marrow cells (not shown).
To further study the potential impact of low MMP levels in bone
homeostasis of S100A4KO mice, WT mice were orally treated for
28 days with a synthetic MMP inhibitor (MMPi) with high afﬁnity
for active MMP2, MMP3, and MMP13, after which the animals were
sacriﬁced and BMD was measured. MMPi-treated animals showed a
16% lower cortical content aswell as a lower estimated functional resis-
tance to bending (moment of inertia, p b 0.001) and twisting (moment
of resistance, p b 0.001) compared to PBS-treated controls (Fig. 2F). The
changes in bone mass of MMPi-treatedmice were remarkably different
from the high cortical content observed in S100A4KO mice, which
indicated that low MMP levels were unlikely to be accountable for
the abnormal bone phenotype in S100A4KO mice.
3.4. Persistent osteoclast formation predicts increased bone turnover in
S100A4-deﬁcient mice
Several levels of evidence indicated that there is increased bone
metabolism in S100A4KO mice. These mice show signs of osteoblast
activation, with 2.25-folds higher expression of LRP5 (p = 0.004)Fig. 2. S100A4-deﬁciency results in low osteoclast formation in vivo. (A1) Sections of undem
trichrome (MGT) staining. Osteoclast (OC) stains intensive red and osteoblast (OB) are pale red,
enumerated along the trabecular perimeter. Immunomorphological staining of the methaphys
(C) and cathepsin K+ (CtsK) osteoclasts (D) in S100A4KO andWTmice. Osteoblasts, TRAP+ a
ular bone and in the growth plate of S100A4KO andWTmice. The bar on themicrophotographs
S100A4KO osteoclasts seldom contained≥3 nuclei (B3). mRNA expression of cathepsin K and c
WT and S100A4KOmice. Expression is normalised to Gapdh and Ppia reference genes. (F) WT
28 days). Total BMD and the bone strength parameters, predicted moment of inertia and mom
(Veh). Low levels of serum MMP3 and MMP9 are measured in S100A4KO and not in MMPi-tr
WT; box-plots are median [IQR] and range, n = 10–12 mice/group).and Runx2 (ns) in the bone marrow (Fig. 3A) and higher serum
levels of the bone matrix protein OC (ng/mL: 118 ± 12 vs 166 ± 19,
p = 0.003) compared to WT mice (Supplementary Table 2). Stimula-
tion of bone marrow cells with recombinant S100A4 revealed that the
expression of LRP5 belongs to the intracellular functions of S100A4
and could not be substituted by extracellular stimulation (Fig. 3A). By
contrast, expression levels of Runx2 andOCwere affected by extracellu-
lar S100A4,with Runx2 induced selectively in S100A4KO cells, while OC
expression was suppressed by recombinant S100A4 independently of
the S100A4-status of stimulated cells. Additionally, S100A4KO mice
had increased osteoclast activation capacity due to lower serum levels
of OPG (p = 0.02) and a relatively high availability of the free
RANK-ligand (Supplementary Table 2).
The in vitro differentiation of osteoclasts from bone marrow pro-
genitors resulted in the formation of high numbers of TRAP+ cells
in S100A4KO cultures compared to WT (Fig. 3B). Morphologically,
S100A4KO osteoclasts were smaller, rounder, and developed fewer cy-
toplasmic protrusions than TRAP+ osteoclasts in WT mice (Fig. 3C1,2).
Additionally, confocalmicroscopyﬁndings supported thesemorpholog-
ical differences, showing that S100A4KO osteoclasts had few cytoplas-
mic protrusions and low expression of surface CD61 (Fig 3C3,4). Flow
cytometry of the bone marrow cells cultured in M-CSF rich media
showed that 72% of osteoclast precursors in S100A4KO mice gained a
CD61+RANK+ phenotype compared to 43–56% in WT mice (Fig. 3D,
upper line). Also, the intensity of CD61 expression was 20% lower
on the surface of S100A4KO compared to WT osteoclast precursors
(p = 0.001. Fig. 3D). The S100A4KO osteoclasts were produced by fu-
sion of 1–3 precursors and contained few nuclei (Fig 3C2,4), while WT
osteoclasts were bigger in size (Fig. 3C1,3) and were multinuclear. The
presence of these paucinuclear osteoclasts in vitro were similar to the
observations done in vivo that osteoclasts along the trabecular struc-
tures in metaphysis of S100A4KO mice rarely had ≥3 nuclear number
(Fig. 2B3). A relationship between the osteoclast phenotype and the ex-
pression of S100A4 was shown by silencing of the S100A4 gene in WT
cells with lentiviral shRNA. S100A4shRNA-treated cells gained the
RANK+CD61+ phenotype and showed low CD61 surface expression
(Fig. 3D, lower line). The S100A4shRNA-treated cells were rounder
and formed less cytoplasmic protrusions (Fig. 3C6) compared to cells
treated with NT-RNA (Fig. 3C5).
3.5. Low surface integrin expression induces morphological changes and
insufﬁcient matrix attachment in S100A4-deﬁcient osteoclasts
Integrins are crucial for the survival, motility and adhesion of
osteoclasts (Fig. 3C3,4). They are also an important component of
podosomes in the sealing zone of these cells, as they are responsible
for resorptive pit separation [37]. Flow cytometry showed that the ex-
pression of integrins was lower in the freshly isolated bone marrow
monocytic cells of S100A4KO mice (Fig. 3E). A particularly prominent
difference was seen in surface expression of the α2- and α5-chains
(which were N2.5-fold lower in S100A4KO cells than in WT cells)
and the β3- and β2-integrins. This low surface expression of integrins
opposed the 6–40-fold higher mRNA levels of these integrins in the
bone marrow of S100A4KO mice compared to WT mice (Fig. 3E), which
made the actual difference in integrin expression of S100A4KO and WT
bone marrow cells even bigger. Stimulation of bone marrow cells withineralised femoral bone of S100A4KO and WT mice were subjected to Masson–Goldner
indicated by arrowheads. (A2) Osteoclasts and osteoblasts within the trabecular areawere
eal region of trabecular bone shows low number of osteocalcin + osteoblasts (B), TRAP+
nd cathepsin K+ cells (stained red, indicated by arrowheads) were enumerated in trabec-
corresponds to 100 μm. The nucleiwithin each TRAP+cellwere counted and showed that
athepsin L (E1) andMMP3, MMP9 andMMP13 (E2) wasmeasured in bonemarrow cells of
mice were treated with a non-selective MMP inhibitor PD166793 (MMPi, 30 mg/kg/d for
ent of resistance, are shown inMMPi-treated and in control WTmice treated with vehicle
eated WT mice. (*P b 0.05, **P b 0.001, ***P b 0.0001, Mann–Whitney test, S100A4KO vs.
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β3-integrin levels, both in WT and in S100A4KO cultures (Fig. 3F).
These integrin chains comprise essential subunits for the receptors of col-
lagen type I (α2β1), ﬁbronectin (α5β1), and vitronectin (αvβ3), and their
deﬁciency provides a structural explanation for the defective adhesion of
S100A4KOosteoclasts to thesematrix proteins. To studywhether the low
surface expression of integrins has a functional signiﬁcance, the motility
of S100A4KO andWT bonemarrow cells was assessed by their migration
towards M-CSF. We observed that S100A4KO cells were capable of early
migration (1 h), with the number of migratory cells continuing to in-
crease after 15 h, at which point the migratory potential of WT cells de-
creased (Fig. 3G). The migration results are consistent with high
motility of S100A4 leukocytes and the reduced adhesion capacity of
S100A4KO cells.
4. Discussion
The present study shows that S100A4 protein deﬁciency is associ-
ated with disturbed bone metabolism, the cumulative result of which
is excessive bone mass, i.e., osteopetrosis. Indeed, in S100A4KO mice,
bone tissue was characterised by an increase in the number and
thickness of the trabeculae and in the thickness of lamellar cortical
bone. The differences in bone mass were pronounced at an early
age and levelled-off after the age of 20 weeks. Selective inhibition of
S100A4 gene transcription was also associated with excessive bone
mass. A 5-week acute inhibition of S100A4 in mature mice resulted
in a signiﬁcant accumulation of cortical bone in WT mice, which sug-
gests an essential regulatory contribution of S100A4 in the process of
bone formation. Histologically, S100A4KO bone showed increased
cellularity, with a higher number of trabecular osteoblasts than was
found in WT bone. At the cellular level, the high bone mass that de-
veloped in S100A4KO mice was consistent with increased osteoblast
activity, as evidenced by the higher levels of Runx2 and LRP5 mRNA
and the bone matrix proteins, OP and OC. The importance of S100A4
for osteoblast maturation has been reported based on the accumulation
of S100A4 inmesenchymal cells in the vicinity of developing bones and
of the tooth bud [38]. These observations are supported by reports of
high expression of bone sialoprotein and OC in S100A4-deﬁcient cell
clones [20,21]. Downregulation of S100A4 with siRNA was associated
with an increase in the number of mineralised nodules in vitro.
In addition to overactivated osteoblasts, S100A4KO mice showed
lownumber of TRAP+and cathepsin K+osteoclasts attached to trabec-
ular structures in femoral bone. S100A4-deﬁcient osteoclasts contained
low cell nuclei number compared to WT osteoclasts, indicating distur-
bances inmultinucleation. The reduced number of functional osteoclasts
in vivo is in contradiction to the ampliﬁed formation of RANK+CD61+
preosteoclasts and of small TRAP+ cells observed in cultures of
S100A4KO mice. The morphology of differentiated S100A4KO osteo-
clasts in vitro was abnormal, as they exhibited a distorted round
shape, poor ability to spread over the surface, few nuclei, and fewer
podosomes. These observations were not unexpected based on theFig. 3. S100A4-deﬁcient osteoclasts show disturbances in cell morphology and phenotyp
S100A4KO and WT mice. Expression is normalised to Gapdh and Ppia reference genes. C
bone marrow cultures with M-CSF and different concentrations of recombinant S100A4. (
the presence of M-CSF (10 ng/ml) and RANKL (5 or 20 ng/ml) were stained for TRAP an
S100A4KO and WT cultures. S100A4KO osteoclasts (C2,4) are smaller in size and develop few
tures showed smaller adherent surface and few nuclei in S100A4KO cells (C4) compared t
(CD61) is shown in red. Actin ﬁlaments are stained with phallacidin-Bodipy FL (green). WT
(C6,6a) were smaller in size and had few cytoplasmic protrusions compared to cells cultured
S100A4 (red) at the leading edge of the cells in the vicinity of actin structures (green) (C5,5a
(CD61) were analysed in the bone marrow-derived osteoclast precursors of WT and S1
S100A4-shRNA and non-targeting lentiviral constructs. S100A4KO cultures (upper row) an
larger population of RANK+CD61+ osteoclast precursors. Both S100A4-deﬁcient cultures h
is measured on bone marrow mononuclear cells of S100A4KO and WT mice by ﬂow cytomet
on bone marrow cells of S100A4KO andWTmice following stimulation with recombinant S1
row cells towards M-CSF (50 ng/ml) was studied in the trans-well system for 1, 3 and 15 h
***P b 0.0001, Mann–Whitney test, median [IQR] and range, n = 7–12 mice/group).current understanding of the role of S100A4 in cell motility and adhesion
during tumourmetastasis [2] and in bonemarrow-derivedmacrophages
[39]. S100A4-deﬁcient macrophages form small and unstable protru-
sions, which resulted in severely altered chemotaxis in vitro and in a
poor mobilisation of macrophages to the inﬂammation site in an acute
thioglycolate-induced model of peritonitis [39]. Poor inﬂux of inﬂamma-
tory cells in the joints of S100A4KOmicewas recently reported in a septic
arthritismodel [16]. In fact, cellmotility is thought to be theprimary func-
tion controlled by S100A4 through its interaction with cytoskeletal pro-
teins, namely, F-actin, tropomyosin, and non-muscle myosin II [16]. The
molecular basis of the high motility and dysfunctional adhesion seen in
our S100A4KO experimental model is likely related to the reduced
surface expression ofα5- andβ1-integrins, as both integrins are vital sub-
units of the receptors that bind extracellular matrix proteins [40]. Addi-
tionally, the expression of integrins is related to cell survival. Inhibition
of S100A4 in tumour cell lines through RNA interference results in
downregulation of α5 and αv integrin expression at the transcriptional
level and promotes apoptosis of detached cells [25]. We observed high
integrin gene transcription and a relatively decreased surface expression
of the same integrins in bonemarrow cells, whichmay be explained by
an increased integrin turnover and/or by suppressed protein translation
in the absence of S100A4. Extracellular stimulation with recombinant
S100A4 induced similar expression of integrins on the surface of
S100A4KOcells andWT cells. This implies functional protein translation
and favours dysfunctional upregulation and stabilisation of integrins on
the surface of S100A4KO cells.
In addition to the effects on cell motility and adhesion, the expres-
sion of β3-integrin is required for proper sealing of the osteoclast re-
sorptive pit. Low levels of β3-integrin may, at least in part, explain the
poor resorptive capacity of S100A4KO osteoclasts in vivo. Deﬁciencies
in podosome-associated proteins, such as MMPs and cathepsins, are
described among the molecular mechanisms resulting in insufﬁcient
bone resorption. Extracellular S100A4 stimulates production of
MMP13 via its interaction with surface-bound RAGE [8], and by tran-
scriptional regulation of MMP9 [28] andMMP13 [41] binding the pro-
moter regions of the respective genes. We observed inconsistency
between low protein levels of MMP9 and MMP3 and high mRNA levels
of MMP9 in S100A4KO mice, while mRNA levels of MMP3 were similar
to those of WT mice. This observation together with the discrepancy in
mRNA and protein levels of integrins suggests that S100A4 may be im-
portant for post-translational stabilisation of these proteins.
The role of MMP deﬁciency in the development of the excessive
bone mass phenotype in S100A4KO mice is uncertain. In studies on
MMP knock-out mice, MMP2-deﬁcient animals showed cranio-facial
abnormalities and developed osteoporosis [42]. Consistently, mice
with targeted mutations to the MMP9 and MMP13 genes exhibited
defective endochondral bone development associated with enlarged
hypertrophic zones, poorly aligned chondrocyte columns, and progres-
sive lengthening of the growth plate of long bones [29,43]. Despite
multiple deﬁciencies in MMPs, abnormalities in joint and cartilage de-
velopment, which are characteristic of double MMP9/MMP13-deﬁciente. (A) mRNA expression of LRP5 and Runx2 was measured in bone marrow cells of
hanges in mRNA expression of Runx2, LRP5 and osteocalcin following stimulation of
B) Osteoclasts derived from bone marrow of WT and S100A4KO mice by culturing in
d enumerated (C12). Representative picture of TRAP+ osteoclasts (red) is shown in
cytoplasmic protrusions compared to WT(C1,3). Confocal microscopy of osteoclast cul-
o WT osteoclasts (C3). Nuclei are stained with DAPI (blue). Expression of β3-integrin
bone marrow cells were cultured in the presence of S100A4-shRNA lentiviral construct
with non-targeting RNA construct (C5,5a). Confocal microscopy showed accumulation of
). Nuclei are stained with DAPI (blue). (D) Surface expression of RANK and β3-integrin
00A4KO mice on day 3 with M-CSF, by ﬂow cytometry. WT cultures treated with
d WT cultures treated with S100A4-shRNA construct (bottom row) had a signiﬁcantly
ad low intensity of CD61 expression. (E) The mRNA and surface expression of integrins
ry. Data are normalised against WT bone marrow cells. (F) Changes of surface integrins
00A4 are normalised to cells cultured in conditional media. (G) Migration of bone mar-
. S100A4KO cell cultures showed prolonged migration capacity. (*P b 0.05, **P b 0.001,
2662 M.C. Erlandsson et al. / Biochimica et Biophysica Acta 1833 (2013) 2653–2663mice, were not observed in S100A4KO mice. Similarly, WT mice treated
with a non-selective synthetic inhibitor of MMP developed increased
bone fragility; this phenotype is in clear contrast to the high cortical
mass seen in S100A4KO mice in this study.
In naturally developed osteoclasts of S100A4KO mice, the pro-
tein levels of MMPs and cathepsin K were lower than in WT mice.
S100A4KO mice also had signiﬁcantly less TRAP+ and cahepsin
K+ osteoclasts in the growth plate area and along the cortical bone
thanWT mice. Cathepsin K is the major cysteine protease of the osteo-
clast resorptive pit as reviewed by Lazner [44], and is crucial for
the breakdown of the collagen network and triple-helical collagens in
lysosomes. The critical role of cathepsin K in bone remodelling is
supported by the ﬁnding that a deﬁciency in cathepsin K activity leads
to an autosomal recessive bone-sclerosing disorder characterised by
osteosclerosis and short stature in men [45]. A similar osteopetrotic
phenotype is seen in cathepsin-K-deﬁcient mice [46]. In the S100A4KO
mice used in this study, cathepsin K activity of trabecular-adherent
osteoclasts and bone marrow osteoclast progenitors was lower than
that in WT mice. Moreover, the S100A4KO mice exhibited signs of an
osteopetrotic phenotype in trabecular and cortical bone, together with
shorter femurs. In the absence of cathepsin K, MMPs may be recruited
for bone resorption [47], which in turn requires cathepsin L. Thus
S100A4 appears to be a common inducer of proteases as both MMP
and cathepsin expression levels were low in S100A4KO mice. Fur-
thermore, since all nuclei of osteoclasts are transcriptionally active
[48], paucinucleation in S100A4KOmice may be an additional mech-
anism accounting for the low cathepsin K and TRAP levels in
S100A4-deﬁcient osteoclasts. The reduced number of functional
osteoclasts in vivo is in contradiction to the increased formation
of RANK+CD61+ preosteoclasts in cultures of S100A4KO mice. The
present study outlines an essential molecular basis for this discrepancy,
including impaired adhesion capacity and poor multinucleation of
S100A4 osteoclasts, as well as the low expression of the proteolytic
enzymes cathepsin K, MMP3 and MMP9 to break down the organic
matrix.
In conclusion, we have shown that S100A4 deﬁciency in mice is
associated with a generalised increase in bone mass, resulting from
a low number of osteoclasts and activation of osteoblasts. The molec-
ular mechanisms responsible for the dysfunctional osteoclasts include
the reduced expression of integrins, which contribute to the formation
of receptors for extracellular matrix proteins within the sealing zone
of the resorptive pit of osteoclasts, and the low expression of cathepsin
K, which is required for the cleavage of the triple helical structure of
mineralised collagen. Taken together, our results are consistent with
the role of S100A4 as a negative regulator of bone metabolism. The
overexpression of S100A4 protein, which occurs in RA and other
inﬂammation-driven diseases, may be responsible for the excessive
bone turnover and osteoporosis characteristic of these conditions.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2013.06.020.
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